Trial Profile

A retrospective, multicentre study evaluating the FDG-PET biomarkers associated with long-term benefit (LTB) and survival in advanced non-small cell lung cancer (NSCLC) patients receiving first-line immunotherapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Aug 2021 Primary endpoint (long-term benefit (defined as patients with complete response (CR), partial response (PR) or stable disease (SD) as best overall response (BOR) maintained for ≥12 months)) has been met, according to the results published in the Annals of Nuclear Medicine.
18 Aug 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com